Report: Siemens Healthcare a Refocused IVD Competitor in 2015
NEW YORK, Feb. 12, 2015 /PRNewswire/ -- Siemens Healthcare underwent many changes in 2014 designed to focus the company towards its successful molecular and immunoassay products. The German healthcare company remains the third—largest company competing in multiple areas of the in vitro diagnostics (IVD) market, according to Kalorama Information. The healthcare market research publisher made the finding in its report Siemens Healthcare Company Profile.
The report can be obtained at: http://www.kaloramainformation.com/Siemens-Healthcare-Company-8693183/.
The report noted the following changes in Siemens Healthcare's organization which are designed to allow the unit to concentrate on high-performing areas of the IVD market.
- In August 2014, Siemens announced its plan to sell its hospital information system business to the U.S.-based company Cerner Corp. In fiscal 2014, the hospital information system business, formerly included in the Healthcare Sector, was classified as a discontinued operation.
- Siemens announced in November 2014 the sale of its hearing aid business. Audiology Solutions to the investment company EQT and the German entrepreneurial family Strüngmann as co-investors.
- Siemens sold its microbiology division to Beckman Coulter.
The report said that Siemens' molecular diagnostics business is based in Bayer's Trugene and Versant molecular lines of tests and systems. The company is betting on new systems - RAPID2 and VERSANT kPCR Molecular System for the future. These are now available in Europe and are undergoing FDA approval in the U.S. These have already been used to sequence viruses (H1N1) and bacteria (MRSA) and produce quantitative results that may be used to monitor response to therapy.
The report also said that Siemens is a top name in immunoassays. Since its introduction in 1992 by DPC, the IMMULITE family of systems has grown to be a premier brand in immunoassay testing. The tests complement Siemens' (Bayer) ADVIA Centaur systems. Together, they have a large global installed base in hospital clinical laboratories. Featured assays include the IMMULITE 2000 Systems Anti-CCP IgG assay for rheumatoid arthritis, ADVIA Centaur Vitamin D Total assay and Dimension Vista LOCI Vitamin B12 assay. In 2013, Siemens added an anti-cyclic citrullinated peptide IgG assay for rheumatoid arthritis to the test menus of its Immulite 2000/2000 XPi immunoassay systems, and LOCI CA 19-9 and enhanced LOCI vitamin B12 assays to the test menus of its Dimension Vista 1500 and Vista 500 systems. The changes will allow the company to focus on competing in these areas.
Kalorama's report looks at the top three IVD companies and Siemens place in it and provides 2013 segment-level IVD revenue estimates for the company. Siemens Healthcare: Company Profile can be obtained at: http://www.kaloramainformation.com/Siemens-Healthcare-Company-8693183/
About Kalorama Information
Kalorama Information, a division of MarketResearch.com, supplies the latest in independent medical market research in diagnostics, biotech, pharmaceuticals, medical devices and healthcare; as well as a full range of custom research services. We routinely assist the media with healthcare topics. Follow us on Twitter, LinkedIn and our blog at www.kaloramainformation.com.
Contact:
Bruce Carlson
(212) 807-2622
[email protected]
www.KaloramaInformation.com
Logo - http://photos.prnewswire.com/prnh/20140801/132634
SOURCE Kalorama Information
Share this article